Roswell Park Cancer Center said this week that Agilent Technologies has licensed its blood cancer assay, PanHeme.

Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples.

Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.

MGI Tech said on Thursday that it has signed a memorandum of understanding with South Korean life science tools distributor Bio-Medical Science (BMS) to bring its next-generation sequencing products to South Korea.

MGI Tech said last week that its DNBSeq-G99 sequencer has been approved as a medical device by China's National Medical Products Administration (NMPA).

Oxford Nanopore Technologies and IQVIA have struck a partnership to broaden access to nanopore sequencing technology, saying it will boost genomics research and patient care.

South Korean next-generation sequencing-based diagnostic firm NGeneBio said on Friday that it has entered a collaboration agreement with Chinese sequencing platform company MGI Tech to expand the commercial access of NGeneBio's cancer testing products.

MGI Tech reported on Friday that its first-half 2023 sequencing revenues rose 40 percent while total revenues dropped 39 percent.

Next-generation sequencing data analysis platform company One Codex said on Thursday that it has formed a partnership with Swiss clinical product manufacturer 4bases to bring sample-to-report microbiome analysis solutions to clinicians in the EU.

Oxford Nanopore Technologies (Oxford Nanopore) and leading China-based diagnostic companies, Zheijiang Digena Diagnostic Technology Co. Ltd (Digena) and Wuhan Dgensee Clinical Laboratory Co., Ltd (Dgensee), today announced a series of strategic collaborations that aim to bring nanopore sequencing technology and instruments to the clinical market in China.